Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 2, 2013, Pages 131-138

  Jabbour, Elias ^a   Garcia Manero, Guillermo ^a   Ravandi, Farhad ^a   Faderl, Stefan ^a   O'Brien, Susan ^a   Fullmer, Amber ^a   Cortes, Jorge E ^a   Wierda, William ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute myeloid leukemia; chronic; Decitabine; Myelodysplastic syndromes; Myelomonocytic leukemia; Risk factors

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHROMOSOME 5; CHROMOSOME 7; CHROMOSOME ABERRATION; DISEASE COURSE; DRUG DOSE COMPARISON; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; SEPSIS; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT DURATION;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; ODDS RATIO; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84877314620     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.11.001     Document Type: Article

References (20)

1. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines on Oncology: Myelodysplastic Syndromes http://www.nccn.org Accessed: March 2, 2011
2. E. Jabbour, J.P. Issa, G. Garcia-Manero Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies Cancer 112 2008 2341 2351
3. G. Leone, L. Teofili, M.T. Voso DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias Haematologica 87 2002 1324 1341 (Pubitemid 36005306)
4. Dacogen [package insert] 2010 Eisai Inc. Woodcliff Lake, NJ
5. P.A. Jones, S.M. Taylor Cellular differentiation, cytidine analogs and DNA methylation Cell 20 1980 85 93 (Pubitemid 10117303)
6. A. Pinto, V. Zagonel 5-aza-2'-deoxycytidine (decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends Leukemia 7 suppl 1 1993 51 60 (Pubitemid 23184801)
7. H.M. Kantarjian, S. O'Brien, J. Shan Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome Cancer 109 2007 265 273 (Pubitemid 46106241)
8. H. Kantarjian, J.P. Issa, C.S. Rosenfeld Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 2006 1794 1803
9. B.D. Cheson, J.M. Bennett, H. Kantarjian Report of an international working group to standardize response criteria for myelodysplastic syndromes Blood 96 2000 3671 3674
10. D.P. Steensma, M.R. Baer, J.L. Slack Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial J Clin Oncol 27 2009 3842 3848
11. B.D. Cheson, P.L. Greenberg, J.M. Bennett Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia Blood 108 2006 419 425 (Pubitemid 44061337)
12. H. Kantarjian, S. O'Brien, F. Ravandi Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original international prognostic scoring system Cancer 113 2008 1351 1361
13. G. Garcia-Manero, J. Shan, S. Faderl A prognostic score for patients with lower risk myelodysplastic syndrome Leukemia 22 2008 538 543 (Pubitemid 351386723)
14. D. Haase, U. Germing, J. Schanz New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients Blood 110 2007 4385 4395 (Pubitemid 351377805)
15. E. Such, J. Cervera, B. Nomdedeu A new prognostic scoring system including transfusion dependency and cytogenetic abnormalities for patients with chronic myelomonocytic leukemia Blood 114 2009 abstract 1750
16. L. Malcovati, M.G. Porta, C. Pascutto Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making J Clin Oncol 23 2005 7594 7603 (Pubitemid 46291823)
17. M.J. Farquhar, D.T. Bowen Oxidative stress and the myelodysplastic syndromes Int J Hematol 77 2003 342 350 (Pubitemid 37121829)
18. C. Hershko, G. Link, I. Cabantchik Pathophysiology of iron overload Ann N Y Acad Sci 850 1998 191 201 (Pubitemid 28369759)
19. M. Lübbert, S. Suciu, L. Baila Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group J Clin Oncol 29 2011 1987 1996
20. R. Itzykson, S. Thépot, B. Quesnel Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine Blood 117 2011 403 411